Core tDCS

tDCS for Depression

tDCS for Depression — Transcranial direct current stimulation (tDCS) can modulate activity in brain regions involved in mood regulation to reduce symptoms of depression. With clinical trials demonstrating robust effects over placebo, tDCS has emerged as an evidence-based treatment option, offering a home-based alternative with minimal side effects to clinic-bound brain stimulation therapies

What is tDCS for Depression?

ttDCS for depression is a specific therapeutic application of transcranial direct current stimulation targeting neural circuits implicated in depressive disorders. The treatment delivers low-intensity electrical current through scalp electrodes positioned to modulate activity in the dorsolateral prefrontal cortex (DLPFC), which is a region involved in mood regulation, emotional processing, and cognitive control.

Depression is associated with characteristic patterns of brain dysfunction. Neuroimaging studies link reduced activity in the left DLPFC with depression. Simultaneously, the right DLPFC often shows excessive activity.

tDCS for depression aims to normalize these dysfunctional patterns. The standard protocol places the anode (positive electrode) over the left DLPFC to increase excitability in this underactive region, while the cathode (negative electrode) is positioned over the right forehead to suppress the excess activity. This approach has been shown to be beneficial across dozens of clinical trials.

How tDCS for Depression Works

tDCS for depression works through multiple neurobiological mechanisms that collectively restore healthier patterns of brain activity and connectivity.

Modulation of Cortical Excitability: The direct current delivered by tDCS shifts neuronal membrane potentials in the targeted regions. Anodal stimulation over the left DLPFC depolarizes neurons, making them more likely to fire in response to natural inputs. This increases activity in a region that is typically underactive in depression. Cathodal stimulation over the right forehead has the opposite effect, reducing excitability. These polarity-specific effects help rebalance the dysfunctional hemispheric asymmetry seen in depression.

Network-Level Changes: Depression involves dysfunction across multiple interconnected brain networks. The cognitive control network (including the DLPFC) is underactive, while the default mode network is often hyperactive. tDCS targeting the DLPFC influences not just the local region under the electrode, but the entire network connected to it. Functional connectivity studies show that tDCS increases connectivity within the cognitive control network.

Neuroplasticity and Structural Changes: Repeated tDCS sessions induce neuroplastic changes—lasting modifications in synaptic strength and neural connectivity. These changes are mediated through mechanisms similar to long-term potentiation (LTP), the cellular basis of learning and memory. Research shows that tDCS increases brain-derived neurotrophic factor (BDNF), a protein crucial for neuroplasticity, synaptic health, and neuronal survival. These neuroplastic changes explain why benefits persist long after treatment completion.

Neurotransmitter Modulation: tDCS studies show effects on dopamine (involved in motivation and reward), GABA (the main inhibitory neurotransmitter), and glutamate (the main excitatory neurotransmitter).

Time Course of Effects: The antidepressant effects of tDCS build gradually. A single session produces temporary changes in cortical excitability lasting hours. Repeated daily sessions over weeks induce cumulative neuroplastic changes that produce sustained therapeutic benefits.

Clinical Evidence for tDCS for Depression

The evidence base for tDCS in depression treatment has grown substantially over the past decade, with multiple randomized controlled trials, meta-analyses, and real-world effectiveness studies.

Landmark Trials

The EMPOWER trial recruited 173 participants from the UK and US for a 10-week at-home treatment course. The trial used a robust placebo-controlled and randomized design, where neither participants or trial staff knew if they were receiving active or placebo treatment. The participants were allowed to maintain ongoing antidepressant medication if they had one during the tDCS treatment. The results showed statistically significant improvement at week 10 endpoint for all used depression measures. Of the participants who received active treatment:

53,7% of patients received more than 50% reduction in symptoms in MADRS questionnaire
47,7% of patients were in remission (without symptoms)

Read the full study: Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial | Nature Medicine

The ELECT-TDCS trial is a double-blind, placebo-controlled trial that enrolled 245 patients to compare tDCS and Escitalopram (a common SSRI) for depression. The treatment period was 10 weeks, where tDCS group had 3 weeks of intensive stimulation followed by 7 weekly treatments, while Escitalopram dose was increased to 20mg during the 10 week protocol. The total number of tDCS sessions was 22 in contrast to 42 in the EMPOWER trial. Of participants who received active treatment, at week 10:

40% received more than 50% reduction in symptoms in MADRS questionnaire
24% were in remission (without symptoms)

Read the full study: Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression | New England Journal of Medicine

The SELECT-TDCS trial compared tDCS to sertraline and to combination treatment in 120 patients with moderate to severe depression. The protocol included 14 tDCS sessions over 6 weeks and 50mg dose of sertraline. At week 6:

43% of the tDCS group and 63% of tdcs+medication group received more than 50% reduction in symptoms in MADRS questionnaire
40% of the tDCS group and 47% of tdcs+medication group were in remission (without symptoms)

Read the full study: The Sertraline vs Electrical Current Therapy for Treating Depression Clinical Study: Results From a Factorial, Randomized, Controlled Trial | Depressive Disorders | JAMA Psychiatry | JAMA Network

Real-World Effectiveness: Beyond controlled trials, real-world effectiveness studies provide important evidence. A retrospective analysis of 462 patients using Sooma tDCS in routine clinical practice showed a clear clinical benefit. Already after 2 to 3 weeks:

55% of patients had received received more than 50% reduction in symptoms
20% were in remission (without symptoms)

Read the full study: Reduction of symptoms in patients with major depressive disorder after transcranial direct current stimulation treatment: A real-world study - ScienceDirect2 months with maintenance sessions

Key Takeaways

tDCS for depression targets brain regions involved in mood regulation, leading to robust benefits both alone and in combination with antidepressant
The treatment modulates activity in the dorsolateral prefrontal cortex, normalizing dysfunctional patterns seen in depression
Effects build gradually through neuroplastic changes

Frequently Asked Questions

How long does it take for tDCS to work for depression?

tDCS for depression works gradually, with most patients noticing initial improvements after 2-3 weeks of daily treatment. The neuroplastic changes linked with long-term benefits build over time and consolidate over continued stimulation throughout the therapy course.

Is tDCS safe for depression treatment?

The scientific evidence and clinical experience with tDCS show only mild and temporary side effects. The most common side effects are: skin tingling during sessions, skin redness at electrode sites, and occasional mild headache. Unlike antidepressant medications, tDCS has not been shown to cause sexual dysfunction, weight changes, gastrointestinal symptoms, or withdrawal effects. tDCS should be only performed using a medical device according to the guidance by the clinician or as instructed by the user manual. Patients belonging to a risk-group should consult a clinician before use. Medical devices such as Sooma include important safety features to ensure treatment safety.